Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Baxter Healthcare Corporation
Integrity assay for meningococcal type B conjugate vaccine developed
June 26th, 2004
Researchers have developed an integrity assay for a meningococcal type B conjugate vaccine. "The development of an analytical procedure for the evaluation of a conjugate vaccine's structural wholeness or integrity is described. The principle component of the vaccine was the N-propionylated group B meningococcal polysaccharide (NPr-GBMP) covalently attached to a carrier protein. The goal of the procedure was to determine whether any whole polysaccharide, oligosaccharide, or monosaccharide, from minute to moderate levels, became detached off the conjugate," scientists in the United States report. "Free saccharide was isolated from the formulation,...
Source: Law & Health Weekly (2004-06-26)
|
